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Xiao-Cong Zeng, Xing-San Li* and Hong WenAbstract
Background: We investigated the potential of telmisartan to improve microvascular dysfunction induced by
myocardial ischemia/reperfusion (I/R) injury by activating the peroxisome proliferator-activated receptor gamma
(PPARG) pathway.
Methods: Forty-eight male rabbits were randomly allocated into sham-operated, I/R, GW9662, telmisartan,
telmisartan–GW9662, or candesartan groups. Rabbits were anesthetized, and the left anterior descending coronary
artery (LAD) was ligated for 60 minutes. Following reperfusion for 6 hours, angiotensin II content of the heart was
determined using radioimmunoassay. Myocardial neutrophil accumulation and microvessel cross-sectional area
were examined histologically. Myocardial capillaries were examined with transmission electron microscopy.
Intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in the myocardium
were measured using enzyme-linked immunosorbent assay. Western blot was utilized for investigating the
expression of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and PPARG.
Results: Angiotensin II concentration was significantly increased in all treatment groups compared with the
sham-operated group (P < 0.05, all). Accumulation of polymorphonuclear neutrophils was significantly lower, while
microvessel cross-sectional area was significantly higher in the telmisartan, telmisartan-GW9662, and candesartan
groups compared with the I/R group (P < 0.05). ICAM-1 and VCAM-1 levels were also significantly lower, and
correlated with lower NF-κB expression in these groups. The effects were the most significant in the telmisartan
group compared with the telmisartan–GW9662 and candesartan groups. Telmisartan significantly increased PPARG
protein expression compared with all other groups (P < 0.05, all).
Conclusions: Except for the typical effects of angiotensin II-receptor blocker, telmisartan improved microvascular
dysfunction during myocardial I/R injury via the PPARG pathway.
Keywords: Ischemia/reperfusion, Microvascular dysfunction, Telmisartan, Peroxisome proliferator-activated
receptor gammaBackground
Reperfusion strategies, including primary percutaneous
coronary interventions and thrombolytic therapy, are
associated with a significant decrease in both short- and
long-term mortality of patients with acute ST segment-
elevated myocardial infarction [1,2]. Recanalization of an* Correspondence: aban829@163.com
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reproduction in any medium, provided the orinfarct-related artery or percutaneous coronary intervention
however does not necessarily guarantee adequate
myocardial perfusion, despite angiographic evidence that
the target stenosis is adequately removed or bypassed [3].
This phenomenon is termed “no-reflow” and results in a
higher incidence of adverse clinical outcomes, including
increased left ventricular remodeling, malignant ventricular
arrhythmias, heart failure, and cardiac death [4]. Although
the mechanisms responsible for no-reflow have not beentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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myocardial hypoperfusion have been proposed, including
capillary plugging by neutrophils, coronary spasm, intracel-
lular or interstitial edema, microvascular flow disturbances
due to platelet aggregation, distal embolization of arterio-
sclerotic debris, and oxygen free radical–mediated endo-
thelial injury [5-7]. Clinical studies have suggested that
microvascular dysfunction is indicative of no-reflow [8].
Although no-reflow clearly results in a poor prognosis,
little guidance is available for the treatment of this
phenomenon. An ideal treatment strategy would involve
drugs with multiple actions on microvascular damage
induced by ischemia/reperfusion (I/R) [9]. Akiyoshi et al.
[10] showed that an angiotensin type 1 receptor (AGTR1)
blockade prevents microvascular dysfunction induced
by I/R injury. Other recent studies have suggested that
peroxisome proliferator-activated receptor gamma (PPARG)
agonists have a protective role subsequent to I/R
damage, and the cardioprotective effects of PPARG activa-
tion are most likely due to inhibition of the inflammatory
response [11,12].
Benson et al. [13] reported that the highly lipophilic
angiotensin receptor blocker (ARB) telmisartan can in-
fluence PPARG target gene expression by functioning as
a partial agonist of PPARG. Telmisartan also induced
PPARG activity in the absence of AGTR1, demonstrating
that its activation is independent of an AGTR1 blockade
[14]. Base on the theory, telmisartan may have more
effects than other ARB without PPARG activity, such as
candesartan. Ikejima et al. [15] reported that telmisartan
has additional effects on nitric oxide bioavailability and
atherosclerotic changes via the PPARG pathway in
genetically hyperlipidemic rabbits. It has also been reported
that telmisartan reduced oxidative stress, apoptosis and
improved cardiac function through PPARG-mediated
effects in diabetic rats with myocardial infarction [16].
Telmisartan has shown new pleiotropic actions through
induction of PPARG activity, providing a potential treatment
mechanism for microvascular impedance induced by I/R
injury.
The present study investigated the role of telmisartan
in preventing microvascular dysfunction, in addition to
its role as an ARB, through its PPARG-mediated effects
during a rabbit myocardial I/R injury model results from a
protocol of 60 minutes of left anterior descending coronary
artery (LAD) ischemia followed by 6 hours of reperfusion.
Methods
Experimental animals
Forty-eight healthy adult male New Zealand white rabbits
(2.0–2.5 kg) were purchased from the Center for Experi-
mental Animals, Guangxi Medical University, Nanning
City, China. Animals were housed at 25 ± 2°C and 60 ± 5%
humidity, and exposed to a 12:12 h light–dark cycle withpellet food and tap water ad libitum. Animal experiments
were performed in accordance with the European
Community Guidelines for the Care and Use of Animals,
and the Institutional Ethics Committee for Animal Usage
approved the research protocol.Modeling and grouping
The 48 rabbits were randomly apportioned into six
groups (n = 8, each). Rabbits of the 6 experimental
groups were given daily doses of the following by gastric
gavage for 14 days: The sham-operated and I/R groups
were administered the vehicle only (0.5% carboxymethyl
cellulose sodium and 10% dimethyl sulfoxide solution).
The GW9662 group received the PPARG antagonist
GW9662 (0.5 mg · kg-1 · d-1; Sigma, St. Louis, MO,
USA). The telmisartan group received the angiotensin
receptor blocker telmisartan (5 mg · kg-1 · d-1; Micardis®,
Boehringer Ingelheim). The telmisartan–GW9662 group
was given telmisartan (5 mg · kg-1 · d-1) and GW9662
(0.5 mg · kg-1 · d-1). The candesartan group received
candesartan (5 mg · kg-1 · d-1; Atacand, AstraZeneca), an
angiotensin receptor blocker without PPARG activity [15].
All animals were anesthetized using 20% urethane via an
ear marginal vein injection. Following midline thoracotomy,
a 4–0 silk ligature was placed under the LAD. The ends of
the suture were threaded through polyethylene tubing to
form a snare. The ends of the suture were pulled tight and
a hemostat was used to clamp the snare to occlude the
coronary artery. After 60 min of ischemia, the ligature was
untied and the snare was loosened, allowing the ischemic
myocardium to reperfuse for 6 h [17]. Sham-operated
animals were subjected to all of the previously described
procedures except ligation of the LAD.Tissue sampling
A cardiectomy was performed, the atrial appendage, atrium
cordis and right ventricle were removed, and the left
ventricle was cut into three transverse sections from the
apex to the base. The base portion of the left ventricle was
cut into a sample of approximately 1 mm3 subendocardial
tissue for examination of the capillary ultrastructure by
electron microscopy. The section from the mid-portion
was used for morphological examination by Hematoxylin
and eosin (H&E) and immunohistochemistry staining.
The apical portion was frozen in liquid nitrogen and
stored at −80°C for assay of myocardial angiotensin-II
concentrations using radioimmunoassay, for determination
of myocardial intercellular adhesion molecule-1 (ICAM-1)
and vascular cell adhesion molecule-1 (VCAM-1) concen-
trations by enzyme-linked immunosorbant assay (ELISA),
for determination of nuclear factor kappa-light-chain-en-
hancer of activated B cells (NF-κB) and PPARG expression
by western immunoblot analyses.
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Myocardial angiotensin-II concentrations were measured
via an iodine-125 radioimmunoassay using an angiotensin-II
radioimmunoassay kit (Beijing North Institute of Biological
Technology, Beijing, China) in accordance with the manu-
facturer’s instructions [18]. Radioactivity was measured
with a GC-1200γ radioimmunoassay counter (Anhui USTC
Zonkia Scientific Instruments, China). Protein concentra-
tions were determined with the Lowry method [19].Morphological examination and assessment of myocardial
neutrophil accumulation
Myocardial morphological and neutrophil accumulation
was examined using H&E staining. A portion of myocardial
tissue from the I/R zone (i.e., the left ventricle anterior wall)
was removed, fixed in 10% formalin, and embedded in
paraffin in accordance with standard laboratory procedures.
After cutting the sample into thin slices, it was stained with
H&E. The number of polymorphonuclear neutrophils
(PMNs) infiltrating into the myocardial tissue, and the
number of PMNs adhering to the capillaries, were
determined per high-power field [20]. For each heart,
PMNs were counted in six fields using three independent
tissue sections by an observer blinded to the experimental
treatment. Counts were averaged.Microvessel cross-sectional area
Myocardial microvessels were highlighted using anti-
Cluster of differentiation (CD)34 (mouse anti-human im-
munoglobulin antibody, Maixin Biology, Fuzhou, China)
immunostaining. A portion of myocardial tissue from
the I/R zone was removed, fixed in 10% formalin,
and embedded in paraffin in accordance with standard
laboratory procedures. After cutting the sample into thin
slices, it was stained using the streptavidin-peroxidase
(Maixin Biology, Fuzhou, China) immunohistochemical
method [21]. A pathological image analysis system
(DMR + Q550, Leica, Wetzlar, Germany) was used to
calculate the cross-sectional area of the microvessels
(μm2), at 400× magnification from 5 visual fields with
the highest density of microvessels [22]. Microvessel
cross-sectional area was considered the mean obtained
in these five fields.Capillary ultrastructure
The ultrastructure of the capillaries was examined using
transmission electron microscopy (H-500, Hitachi, Tokyo,
Japan) of subendocardial tissue from ischemic regions of
the hearts that were subjected to the I/R protocol, as
described above. The tissues were prepared for transmission
electron microscopy as described previously [23].Myocardial ICAM-1 and VCAM-1 concentrations
Myocardial ICAM-1 and VCAM-1 concentrations were
determined using ELISA. Frozen left ventricle tissue
samples were homogenized in lysis buffer containing
Tris–HCl 50 mM, ethylenediaminetetraacetic acid 1 mM,
and 5% sucrose (pH 7.4). The protein concentration was
determined using the Lowry method [19]. ICAM-1 and
VCAM-1 were determined using commercially available
ELISA kits (RapidBio Lab, Calabasas, California, USA) [24].Myocardial NF-κB and PPARG protein expression
The NF-κB and PPARG protein expression were examined
using western blot analysis. Proteins were resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis,
transferred onto a nitrocellulose membrane, and incubated
serially with the rabbit anti-human NF-κB, rabbit anti-
human PPARG, and rabbit anti-human actin polyclonal
antibodies (Santa Cruz Biotechnology, CA, USA) at 4°C
overnight. Proteins were detected using horseradish
peroxidase-conjugated secondary antibody (Santa Cruz
Biotechnology, CA, USA) and visualized using the enhanced
chemiluminescence method [25]. The Bio-Rad Gel
Doc 2000 imaging system and software were used to
calculate the integrated absorbance (IA) of identified
bands: IA = Area × Average density [26]. Following
normalization to β-actin (ACTB) levels, the ratios of the
IAs of NF-κB or PPARG to the Ia of ACTB were used to
represent relative levels of activated NF-κB and PPARG.Statistical analyses
Data are expressed as mean ± standard deviation. Statistical
differences were determined using analysis of variance
(ANOVA); P < 0.05 was considered statistically significant.
All the analyses were performed using SPSS software
(version 16; SPSS, Chicago, IL, USA).Results
Animal groups
No statistically significant differences were found in body
weights or heart rates among the 6 experimental groups
(data not shown).Measurement of Angiotensin-II concentration in the left
ventricle by Radioimmunoassay
The myocardial angiotensin-II concentrations in the treat-
ment groups were: sham-operated, 152 ± 20 pg/mg; I/R,
221 ± 40 pg/mg; GW9662, 226 ± 19 pg/mg; telmisartan,
235 ± 33 pg/mg; telmisartan–GW9662 227 ± 26 pg/mg;
and candesartan 215 ± 39 pg/mg. The angiotensin-II con-
centrations of all the treatment groups were significantly
higher than that of the sham-operated group (P < 0.05).
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H&E staining
In the sham-operated group, the results of H&E staining
show that muscle fibers were integrated and nucleoli
were normal. The muscle fibers of the I/R and GW9662
groups had extensive edema, necrosis, and breakage, and
a large number of dissolved myocyte nucleoli. Also, the
number of PMNs infiltrating the area of the reperfused
myocardium was increased in the I/R (78.38 ± 10.68/
high-power field) and GW9662 (85.38 ± 11.17/high-
power field) groups, compared with the sham-operated
(2.13 ± 1.81/high-power field).
In the telmisartan, telmisartan–GW9662, and candesartan
groups, the muscle fibers showed less breakage and edema,
along with fewer ruptured nucleoli. There was also signifi-
cantly fewer PMN infiltration in the myocardium of the
telmisartan (38.25 ± 14.11/high-power field), telmisartan–
GW9662 (58.63 ± 12.68/high-power field), and candesartan
(53.38 ± 13.57/high-power field) groups, compared with
the I/R and GW9662 groups. Furthermore, there were
significantly fewer PMNs infiltrating the myocardium in
the telmisartan group compared with the telmisartan–
GW9662 and candesartan groups (Figure 1).
Assessment of PMN adherence to microvessels by H&E
staining
The results of H&E staining show that the I/R and
GW9662 groups had neutrophils primarily adheringFigure 1 Assessment of PMN infiltration into the myocardium by H&E st
(a) sham-operated group; (b) I/R group; (c) GW9662 group; (d) telmisartan grou
B) Quantitative analyses of the number of PMNs infiltrating into the myocardiuand plugging the venules, while occasionally also
affecting the arterioles. The number of PMNs adhering
to the microvessels were also increased in the I/R
(34.25 ± 6.41/high-power field) and GW9662 (38.25 ±
6.98/high-power field) groups. However, in the telmisartan
(9.50 ± 3.02/high-power field), telmisartan–GW9662
(20.63 ± 4.27/high-power field), and candesartan (16.25 ±
3.37/high-power field) groups, the neutrophils were
observed adhering and plugging the venules, but scarcely
present in the arterioles, and there were significantly fewer
PMNs adhering to the microvessels in these groups
compared with the I/R and GW9662 groups. The
telmisartan group had significantly fewer PMNs adhering
to the microvessels compared with either the telmisartan–
GW9662 or candesartan group (Figure 2).
CD34-immunostaining of microvessels and microvessel
cross-sectional area
Vascular endothelial cells were visualized by labeling with
CD34. The cross-sectional area of microvessels were lower
all the treatment groups compared with the sham-operated
(80.10 ± 8.47 μm2) group. This decrease in microvessel
cross-sectional area was more significant in the I/R
(37.17 ± 12.86 μm2) and GW9662 (36.17 ± 4.45 μm2)
groups than in the telmisartan (67.19 ± 5.72 μm2),
telmisartan–GW9662 (51.49 ± 6.15 μm2), and candesartan
(53.97 ± 6.46 μm2) groups. The microvessel cross-sectional
area of the telmisartan group was significantly higheraining. A) Micrographs show PMNs infiltrating into the myocardium:
p; (e) telmisartan–GW9662 group; (f) candesartan group; (H&E stain; 400×).
m. *P< 0.05 compared with sham-operated; #P < 0.05 compared with I/R.
Figure 2 Assessment of PMN adherence to microvessels by H&E staining. A) Micrographs showing PMNs adhering to arterioles:
(a) sham-operated group; (b) I/R group; (c) GW9662 group; (d) telmisartan group; (e) telmisartan–GW9662 group; (f) candesartan group;
(H&E stain; 400×). B) Micrographs show PMNs adhering to venules: (a) sham-operated group; (b) I/R group; (c) GW9662 group; (d) telmisartan
group; (e) telmisartan–GW9662 group; (f) candesartan group; (H&E stain; 400×). C) Quantitative analyses of the number of PMNs adhering to
microvessels. *P < 0.05 compared with sham-operated; #P < 0.05 compared with I/R.
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groups (Figure 3).
Assessment of myocardial capillary ultrastructure by
transmission electron microscopy
In the sham-operated group, ultramicroscopic examination
revealed that the capillaries consisted of endothelial cells.
The capillary basement membrane was moderate in thick-
ness, and capillaries contained erythrocytes. In the I/R and
GW9662 groups, endothelial cell swelling led to stenosis
of the capillary lumen and nearly complete obstruction of
the lumen. Close attachment between the leukocyte and
the endothelium was observed. The phenomenon of one
leukocyte plugged a single capillary was found in the I/Rand GW9662 groups. In the telmisartan, telmisartan–
GW9662, and candesartan groups, endothelial cell swelling
was relieved and stenosis of the capillary lumen was
attenuated, while the phenomenon of one leukocyte
plugging a single capillary was not found (Figure 4).
Measurement of myocardial ICAM-1 and VCAM-1 content
by ELISA
The myocardial ICAM-1 content of the treatment
groups were: sham-operated, 1.36 ± 0.30 ng/mg; I/R,
3.30 ± 0.34 ng/mg; GW9662, 3.19 ± 0.40 ng/mg;
telmisartan, 2.06 ± 0.17 ng/mg; telmisartan–GW9662,
2.78 ± 0.20 ng/mg; and candesartan 2.54 ± 0.32 ng/mg.
The myocardial VCAM-1 content was: sham-operated,
Figure 3 Assessment of microvessel cross-sectional area by CD34-immunostaining. A) Photomicrographs of myocardial tissue sections
showing microvessels: (a) sham-operated group; (b) I/R group; (c) GW9662 group; (d) telmisartan group; (e) telmisartan–GW9662 group;
(f) candesartan group (CD34 label, 400×). B) Quantitative analyses of microvessel cross-sectional area. *P < 0.05 compared with sham-operated;
#P < 0.05 compared with I/R.
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4.02 ± 0.30 ng/mg; telmisartan, 3.16 ± 0.30 ng/mg;
telmisartan–GW9662, 3.54 ± 0.37 ng/mg; and candesartan,
3.38 ± 0.29 ng/mg. The myocardial ICAM-1 and
VCAM-1 was significantly higher in all the treatmentFigure 4 Photomicrographs of the ultrastructural changes in rabbit c
was moderate in thickness, and the capillary contained an erythrocyte (770
capillary lumen (7700×); (c) I/R group, one leukocyte plugged a single capi
stenosis of the capillary lumen (7700×); (e) GW9662 group, one leukocyte p
swelling was relieved (7700×); (g) telmisartan–GW9662 group, endothelial c
cell swelling was relieved (7700×).groups compared with that of the sham-operated group
(P < 0.05, all). The increase in cardiac ICAM-1 and
VCAM-1 content was more significant in the I/R and
GW9662 groups than in the telmisartan, telmisartan–
GW9662, and candesartan groups (P < 0.05, all). Cardiacapillaries. (a) sham-operated group, capillary basement membrane
0×); (b) I/R group, endothelial cell swelling led to stenosis of the
llary (7700×); (d) GW9662 group, endothelial cell swelling led to
lugged a single capillary (7700×); (f) telmisartan group, endothelial cell
ell swelling was relieved (7700×); (h) candesartan group, endothelial
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significantly lower than that of the telmisartan–GW9662
and candesartan groups (P < 0.05, all).
Determination of myocardial NF-κB and PPARG protein
expression by Western blot analyses
Western blot analyses revealed that NF-κB protein ex-
pression observed in all treatment groups was higher
compared with that of the sham-operated (0.50 ± 0.08)
group. The increase in NF-κB protein expression was
more significant in the I/R (0.87 ± 0.05) and GW9662
(0.86 ± 0.03) groups than in the telmisartan (0.63 ± 0.05),
telmisartan–GW9662 (0.71 ± 0.07), and candesartan
(0.73 ± 0.05) groups. NF-κB protein expression in the
telmisartan group was significantly lower than that of
the telmisartan–GW9662 and candesartan groups. These
results suggest that in the telmisartan (0.83 ± 0.05),
telmisartan–GW9662 (0.72 ± 0.09), and candesartan
(0.71 ± 0.04) groups, but not the GW9662 (0.53 ± 0.06)
group, PPARG protein expression was significantly higher
compared with the I/R (0.57 ± 0.05) group (P < 0.05, all).Figure 5 Determination of myocardial NF-κB and PPARG protein expr
activated NF-κB protein were determined using Western blot; the IA values
in the representative gel show NF-κB expressions in the sham-operated, I/R
respectively. B) Relative expression levels of activated PPARG protein were
expression. Lanes a, b, c, d, e, and f in the representative gel show PPARG
telmisartan–GW9662, and candesartan groups, respectively. C) Quantitative
sham-operated group; #P < 0.05 versus I/R group. D) Quantitative analyses o
sham-operated; #P < 0.05 compared with I/R.PPARG was significantly higher in the telmisartan group
compared with the telmisartan-GW9662 and candesartan
groups (Figure 5).
Discussion
The present study showed microvascular dysfunction in
the I/R and GW9662 groups, in which microvascular
spasm and intracellular/interstitial edema induced a
decrease in microvessel cross-sectional area, while
neutrophils were adherent and plugged the venules and
occasionally the arterioles, with endothelial cell swelling
leading to stenosis of the capillary lumen. Furthermore,
the myocardial ICAM-1 and VCAM-1 content and
NF-κB protein expression were significantly increased
during myocardial I/R. Our study also showed that
treatment with telmisartan and candesartan exerted
protective effects against microvascular dysfunction
during myocardial I/R by reducing neutrophil aggregation
and adherence, increasing microvessel cross-sectional
area, preventing vascular endothelial cells from swelling,
and reducing intracellular/interstitial edema. Furthermore,ession by Western blot analyses. A) Relative expression levels of
were normalized to ACTB expression levels. Lanes a, b, c, d, e, and f
, GW9662, telmisartan, telmisartan–GW9662, and candesartan groups,
determined using Western blot; the IA values were normalized to ACTB
expression in the sham-operated, I/R, GW9662, telmisartan,
analyses of the expression activated NF-κB protein. *P < 0.05 versus
f the expression activated PPARG protein. *P < 0.05 compared with
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tory marker expression (ICAM-1, VCAM-1 and NF-κB)
during myocardial I/R was significantly decreased. In
addition, protective effects were more evident in the
telmisartan group than in either the candesartan or
telmisartan–GW9662 [15]. It is especially important
that telmisartan significantly increased PPARG protein
expression compared with all other groups.
Recently, the renin–angiotensin system has been shown
to have an important role in I/R -induced myocardial
injury, confirmed by both indirect and direct studies
[27,28]. We found in the present study that angiotensin-II
concentrations in left ventricular tissue increased subse-
quent to myocardial I/R. Activation of NADPH oxidase,
stimulated by angiotensin-II, generates reactive oxygen
species, which in turn may act as signal transduction mes-
sengers for NF-κB. Numerous genes, including interleukin
(IL)-1, IL-6, IL-8, interferon-γ, TNF-alpha, ICAM-1 and
VCAM-1, are stimulated by activation of NF-κB [29]. The
adherence and accumulation of neutrophils is mediated
by ICAM-1 and VCAM-1 [30]. ARBs ameliorated myo-
cardial I/R-induced pathological inflammation by blocking
the AGTR1. This resulted in downregulation of NF-κB
expression, which decreased ICAM-1 and VCAM-1 levels,
and thus attenuated leukocyte adhesion in the coronary
microvasculature. Cell rolling and migration across the
endothelium was reduced, and inhibiting inflammatory
cell infiltration into the myocardium. The key product of
the renin–angiotensin system (angiotensin II) leads to
positive inotropism, coronary vasoconstriction, and
microvascular spasm by increasing intracellular calcium
levels of myocytes and smooth muscle cells [31,32].
Inflammation mediated by neutrophils and microvascular
spasm may increase capillary permeability, thus inducing
intracellular/interstitial edema formation during myocardial
I/R [33]. Both microvascular spasm and microvascular bed
compression due to tissue edema [34] may result in a
decrease in microvessel cross-sectional area. Changes in
total cross sectional vascular area may contribute to the
no-reflow phenomenon [34]. ARBs attenuate myocardial
I/R -induced intracellular/interstitial edema and micro-
vascular spasms by blocking the AGTR1, resulting in an
increase in microvessel cross-sectional area. PPARs are a
family of at least three nuclear receptors (α, δ, and γ),
which regulate genes involved in lipid metabolism, adipo-
cyte differentiation, and inflammation. PPARG activation
regulates activating protein-1, signal transducer and the
activation of transcription and NF-κB pathways, thereby
further inhibiting the production of proinflammatory
mediators and cytokines, attenuating oxidative burst,
inhibiting inducible nitric oxide synthase induction, and
decreasing inflammation [11]. PPARG activation appears
to be a novel mechanism for mediating the beneficial
effects of ARBs [15,16], and may be directly stimulated bytelmisartan [13]. In the present study, histology of the
myocardium revealed that microvascular dysfunction
was significantly more amended with telmisartan than
with either telmisartan–GW9662 or candesartan. Besides
the typical effects of ARBs, telmisartan additionally
improved microvascular dysfunction through PPARG-
mediated effects. PPARG activation may inhibit NF-κB
pathways, thus telmisartan further decreased ICAM-1 and
VCAM-1 expression, attenuating leukocyte adhesion and
infiltration and intracellular/interstitial edema, and further
increasing microvessel cross-sectional area. So, telmisartan
additionally improved microvascular dysfunction than
candesartan, an ARB without PPARG activity. Moreover,
telmisartan–GW9662 significantly decreased telmisartan-
induced protective effects on microvascular dysfunction by
antagonizing PPARG activation.
Recent studies have found that myocardial I/R injury
was prevented by ARB in an animal model [35,36].
Furthermore, Hu T et al. [37] reported that chronic
pre-treatment of ARB was associated with a reduction in
the no-reflow phenomenon in patients with reperfused
acute myocardial infarction (AMI) and could preserve
microvascular integrity following AMI independent of
blood pressure lowering. Therefore, we chose this experi-
mental design to demonstrate that telmisartan has pro-
tective effects, in addition to its role as an ARB, against
microvascular dysfunction during myocardial I/R via the
PPARG pathway. This may be more effective than other
ARBs. Moreover, the findings implied that telmisartan
may be a more effective therapy than other ARBs for
reducing the no-reflow phenomenon in patients with
reperfused AMI. However, some limitations of our study
deserve consideration. First, we found that telmisartan-
GW9662 and candesartan treatment significantly increased
PPARG protein expression compared with the I/R group.
Jugdutt et al. [36] reported that upregulation of angiotensin
type 2 receptor (AGTR2) provides beneficial effects during
AGTR1 blockade in a rat model of myocardial I/R. AGTR2
activation may also augment PPARG-mediated effects by
enhancing binding of nuclear PPARG coactivators and
producing additional endogenous PPARG ligands [38]. This
could explain why treatments with telmisartan-GW9662
or candesartan significantly increased PPARG protein
expression compared with the I/R group. However, we
could not identify which AGTR2 mediated the activation
of PPARG-improved microvascular dysfunction in the
present study. Further studies will be performed on this
important question. Second, our study focused on hist-
ology and inflammatory markers and did not include an
investigation of blood flow. Measurement of regional
myocardial blood flow would be suitable [39]. Therefore,
determination of regional myocardial blood flow will
be used in our future studies. Third, telmisartan is the
most powerful stimulator of PPARG activity among
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activity [15]. So we chose the two drugs for this
experimental design. Moreover,we used equal doses of
telmisartan and candesartan in our study, this referred to
the research of Ikejima et al. [15]. However, 5 mg/kg/d
candesartan may be more powerful than 5 mg/kg/d
telmisartan [40]. It is not clear how such differences may
affect the comparability of our results. Therefore, adminis-
tration of different doses of two drugs will be executed in
our future studies.
Conclusion
Taken together, our study suggests that telmisartan has
protective effects against microvascular dysfunction during
myocardial I/R, in part through PPARG-mediated effects.
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